This video summarizes interesting data from an aqueous vascular endothelial growth factor (VEGF) study presented at this year’s ARVO congress, in Seattle, US (Monday 02 May 2016, 16:45-17:00 PM, Program Number 2317). Patients with diabetic macular edema (DME) received either bimonthly intravitreal injections of ranibizumab (n=12) or aflibercept (n=7). Investigators Sawada et al. from Shiga University reported a significant reduction in median aqueous VEGF concentration from 141.9 pg/mL to 70.0 pg/mL 2 months after ranibizumab injection (P<0.05). Median aqueous VEGF concentration decreased from 160.1 pg/mL to below the lower limit of detection in six of seven eyes, and to 25.7 pg/mL in one eye 2 months after aflibercept injection (P<0.05). The investigators concluded that intravitreal aflibercept injections suppressed VEGF more than ranibizumab injections for 2 months.
Home / Aflibercept injections
Aflibercept injections
Other Perspective
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
High-dose Aflibercept: the PHOTON and PULSAR trials
Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th
What is the current situation of ophthalmology in Ukraine?
Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.